Skip to main content
Moderna, Inc. logo

Moderna, Inc. — Investor Relations & Filings

Ticker · MRNA ISIN · US60770K1079 LEI · 549300EI6OKH5K5Q2G38 US Manufacturing
Open in API
Filings indexed 1,397 across all filing types
Latest filing 2021-04-13 Regulatory Filings
Country US United States of America
Listing US MRNA

About Moderna, Inc.

https://www.modernatx.com/

Moderna, Inc. is a biotechnology company pioneering the development of messenger RNA (mRNA) therapeutics and vaccines. The company's core platform utilizes mRNA to carry instructions that direct the body's cells to produce proteins, thereby preventing or treating diseases. This technology enables the rapid design, research, and production of new medicines. Moderna is widely recognized for developing one of the first COVID-19 vaccines. Its research and development pipeline extends to various therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, and autoimmune disorders. The company's mission is to create a new generation of transformative medicines for patients by leveraging the potential of its mRNA platform.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an update on vaccine doses delivered during the quarter ended March 31, 2021, and references a press release as Exhibit 99.1. The document explicitly states it is a Current Report and does not contain detailed financial statements or comprehensive financial analysis. It is not an earnings release or annual/interim report but rather a regulatory filing to disclose material information promptly. The document length is 3744 characters, which is relatively short and consistent with a Form 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2021-04-13 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-13 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-13 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-13 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a statement issued by Moderna regarding safety data of its COVID-19 vaccine, specifically about the absence of association with certain thrombotic events. The document is short (3251 characters) and does not contain financial statements or detailed financial analysis. It is a regulatory announcement of a specific event or disclosure rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2021-04-13 English
PRIMARY DOCUMENT
Director's Dealing
2021-04-09 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.